PatternsRadar
Sign in

PPLPHARMAPiramal Pharma Limited

NSE
239.30INR-0.35 (-0.15%)Close · 20 Nov 2026
27 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹31,859 CrMarket cap
—P/E (TTM)
45.6%Delivery

Filings & corporate actions

17 results filed
CSV
Next results · Q3 FY27
Expected 28 Jan 2027 – 9 Feb 2027
Estimate: filed 28–40 days after quarter end, last 4 times
Dividend
₹0.14 per share · last 16 Jul 2025
2026
  • 27 OctresultsResults · Q2 FY27 · consolidated and standalone+17.1%NSE
  • 21 OctshareholdingShareholding · 30 Sept 2026-1.7%NSE
  • 29 JulresultsResults · Q1 FY27 · consolidated and standalone+0.5%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-0.3%NSE
  • 28 AprresultsResults · Q4 FY26 · consolidated and standalone-2.6%NSE
  • 20 AprshareholdingShareholding · 31 Mar 20260.0%NSE
  • 29 JanresultsResults · Q3 FY26 · consolidated and standalone-0.2%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-4.0%NSE

Reaction to results · all yearsrose on day 0 in 10 of 17 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2727 Oct 2026+17.1%+19.6%—50.8×
Q1 FY2729 Jul 2026+0.5%+6.4%+9.8%2.7×
Q4 FY2628 Apr 2026-2.6%+11.7%+5.1%1.0×
Q3 FY2629 Jan 2026-0.2%+5.3%+4.6%5.7×
Q2 FY265 Nov 2025-0.5%-3.3%-9.8%4.8×
Q1 FY2628 Jul 2025+0.6%-5.3%-8.8%2.9×
Q4 FY2514 May 2025-4.8%-5.8%-8.7%4.1×
Q3 FY2528 Jan 2025+9.5%+3.9%-3.6%2.8×
Q2 FY2523 Oct 2024+17.4%+23.2%+14.8%13.2×
Q1 FY2526 Jul 2024+0.1%+4.8%+12.6%6.0×
Q4 FY2410 May 2024+2.5%-0.6%+4.5%9.3×
Q3 FY2430 Jan 2024+3.8%+0.3%-6.3%3.0×
Q2 FY2428 Oct 2023+3.2%+17.3%+31.9%6.9×
Q1 FY243 Aug 2023-2.4%-7.1%-1.2%0.8×
Q4 FY2325 May 2023+5.2%+4.4%+15.5%3.4×
Q3 FY239 Feb 2023-9.9%-7.9%-27.2%5.7×
Q2 FY2310 Nov 2022-1.6%-4.8%-7.8%—
Average+2.2%+3.6%+1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+28.1%
Profit YoY—
Interest cost YoY-7.4%
Revenue QoQ+15.3%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+6.0%+9.1%————
Profit——————

Key data

Open236.21
Day range234.32 – 242.24
52-week range132.30 – 253.90
From 52w high-5.8%
RSI (14)62.3
ATR (14)8.51
Volume39.11L
Avg volume (20D)1.23Cr
Rel volume0.32×
Volatility (1Y)37.5%
Turnover₹92.8Cr
Traded value (NSE)₹92.8Cr
VWAP237.17
SMA 50 / 200215.87 / 183.01
Price band20%

Delivery percentage

Latest · 20 Nov 202645.6%
20-day avg39.4%
1-year avg38.7%
Percentile (own history)57th
Range5.8–100.0%
Sessions1,014

Over the last 20 sessions PPLPHARMA settled 39.4% of its traded quantity, which is ordinary for an NSE equity. That is in line with its own one-year average of 38.7%. The latest session ranks higher than 57% of the 1,014 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders4.13L · -10.4% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy638 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.15%-2.14%+22.72%+10.45%+35.90%+23.33%

Valuation

Market cap₹31,859 Cr
Market cap (NSE)₹31,859 Cr
Free-float cap₹20,772 Cr
P/E (TTM)—
P/E (NSE)—
EPS (TTM)-1.57
P/B3.9
Net margin (TTM)-2.1%
Other income / PBT—
ROE-2.6%
Debt / equity0.69
Shares outstanding132.84Cr
Listed19 Oct 2022

Ownership

Promoter34.80%
Promoter Δ QoQ0.00 pp
Public64.80%
FII13.65%
DII14.44%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)2,139.92,751.82,269.92,617.1
YoY chg-2.9%-0.1%+17.4%+28.1%
Net profit (₹ Cr)(136.2)(8.8)(69.4)5.0
YoY chg-3800.8%-105.7%——
Net margin-6.4%-0.3%-3.1%0.2%
EPS-1.03-0.07-0.520.04

Shareholding over time

By quarter

30 Sept 2026 · promoter 34.80% · public 64.80%
18 Oct 2022: promoter 34.79%31 Dec 2022: promoter 34.79%31 Mar 2023: promoter 34.79%30 Jun 2023: promoter 34.79%22 Aug 2023: promoter 35.02%27 Sept 2023: promoter 35.02%30 Sept 2023: promoter 35.02%31 Dec 2023: promoter 35.02%31 Mar 2024: promoter 35.02%30 Jun 2024: promoter 34.95%30 Sept 2024: promoter 34.95%31 Dec 2024: promoter 34.95%31 Mar 2025: promoter 34.95%30 Jun 2025: promoter 34.86%30 Sept 2025: promoter 34.86%31 Dec 2025: promoter 34.86%31 Mar 2026: promoter 34.86%30 Jun 2026: promoter 34.80%30 Sept 2026: promoter 34.80%
2022-102026-09
  • Promoter
  • Public and others
Promoter
34.80%
Public
64.80%
Promoter change
0.00 pp
Filed
21 Oct 2026
FII
13.65%
DII
14.44%
Promoter pledged
0.00%

Who the public is

Mutual funds
12.71%

-0.47 pp QoQ

Insurance
1.23%

+0.21 pp QoQ

FPI
13.65%

+1.14 pp QoQ

Retail ≤ ₹2L
9.62%

-1.40 pp QoQ

HNI > ₹2L
3.65%

+0.13 pp QoQ

NRI
1.08%

-0.01 pp QoQ

Bodies corporate
1.62%

+0.48 pp QoQ

Shareholders
4,13,197

-10.4% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal)Promoter · Other26.51%
Ca Alchemy InvestmentsCorporate17.93%
Hdfc Trustee Company Limited-Hdfc Flexi Cap FundMutual fund5.65%
V3 Designs LLPPromoter · Corporate3.23%
PRL Realtors LLPPromoter · Corporate2.99%
East Bridge Capital Master Fund I LtdFPI2.00%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap FundMutual fund1.56%
Indiahold LimitedCorporate1.30%
Piramal Welfare TrustPromoter · Other0.79%
Semplice Corporate Solutions Private LimitedPromoter · Corporate0.67%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 12 Jul 2024 CSV
Financial yearPaymentsDeclaredAdjusted
FY2025-261₹0.14₹0.14
FY2024-251₹0.11₹0.11
Ex-dateRecord dateDeclaredAdjusted
16 Jul 2025—₹0.14₹0.14
12 Jul 2024—₹0.11₹0.11

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Bulk & block deals · 20 Feb 2025

CSV
6 of 6 deals
By year
DateDealClientQuantityPriceValue
20 Feb 2025Sell · bulkGRAVITON RESEARCH CAPITAL LLP68.57L219.88₹150.8Cr
20 Feb 2025Buy · bulkGRAVITON RESEARCH CAPITAL LLP68.57L219.70₹150.6Cr
16 Jun 2023Sell · bulkCAISSE DE DEPOT ET PLACEMENT DU QUEBEC1.06Cr94.48₹99.9Cr
16 Jun 2023Buy · bulkTHE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND62.03L94.71₹58.7Cr
1 Nov 2022Sell · bulkBLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L1.41Cr158.88₹223.5Cr
1 Nov 2022Buy · bulkBLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L3.10L158.49₹4.9Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026
  • Zero EPS (4 quarters) · since 12 Jan 2026 — Zero EPS over the last four quarters.

Price band: 20% · not in the F&O ban · 0.0% of the market-wide position limit used.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes · MWPL.

Every stock on this session →

Futures & options · 28 Apr 2026

CSV

Long unwinding — price down as positions closed — longs exiting.

Futures OI
20.37L

₹33.5Cr

OI change
-44.01%
Basis
-0.15%
Rollover
0.0%
PCR (OI)
1.01
PCR (volume)
0.75
Front settle
164.47
Lot size
2,625

shares

Futures volume
1.6K

contracts

Futures trades
1,406
Futures value
₹67.7Cr
Sessions shown
226

Open interest is in shares (index units for an index), summed over every expiry; volume, trades and traded value too. Settle and lot size are the front future’s. Buildup compares the close’s direction with the change in futures OI across the contracts still open, so an expiring contract does not read as unwinding. Scan it with pattern is long_buildup.

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue from operations1,958.62,552.41,951.12,241.82,204.22,754.11,933.72,043.72,139.92,751.82,269.92,617.1
Other income61.526.419.561.112.142.058.465.643.246.189.435.9
Total income2,020.12,578.71,970.72,302.92,216.42,796.11,992.12,109.32,183.12,797.82,359.32,653.0
Total expenses1,982.42,332.82,038.22,200.02,166.62,539.52,110.42,170.32,246.12,592.62,386.42,589.1
└ Finance costs105.9114.2107.0107.6103.3103.786.282.489.283.088.187.6
└ Depreciation186.3196.1184.6192.2196.8242.8197.3202.8212.7218.4223.6233.2
Profit before tax5.4215.4(67.5)102.949.8256.6(97.6)(61.0)(104.1)29.4(27.0)63.9
Tax expense9.3126.243.697.563.1119.32.753.042.351.861.976.6
Net profit10.1101.3(88.6)22.63.7153.5(81.7)(99.2)(136.2)(8.8)(69.4)5.0
EPS0.080.77-0.670.170.031.16-0.62-0.75-1.03-0.07-0.520.04
Net margin0.52%3.97%-4.54%1.01%0.17%5.57%-4.23%-4.85%-6.36%-0.32%-3.06%0.19%
PBT margin0.28%8.44%-3.46%4.59%2.26%9.32%-5.05%-2.98%-4.87%1.07%-1.19%2.44%
Tax rate170.98%58.58%—94.82%126.87%46.50%———176.11%—119.89%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 27 Oct 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets14,522.614,775.715,311.815,241.715,677.616,189.417,965.018,537.2
Current assets4,835.54,954.05,464.55,381.75,797.05,953.07,191.77,253.7
└ Cash & equivalents195.6251.5356.8270.3369.0499.41,199.9545.0
└ Other bank balances112.0284.5125.7127.7132.522.123.823.6
└ Current investments427.159.1144.710.419.6222.5131.8261.4
└ Trade receivables1,799.31,743.42,134.41,827.12,349.51,984.62,157.72,253.7
└ Inventories1,681.42,060.52,175.92,447.42,312.72,742.83,064.43,294.8
Total equity6,773.57,757.97,911.47,907.28,125.58,073.88,162.68,164.7
└ Attributable to owners6,773.57,757.97,911.47,907.28,125.58,073.88,162.68,142.2
└ Non-controlling interest—0.0——0.0—0.022.5
└ Share capital1,193.31,323.01,323.01,323.11,324.41,325.51,327.21,328.4
Borrowings5,504.84,404.04,558.94,643.14,720.34,715.45,495.55,665.3
└ Current2,121.21,542.92,075.13,108.11,506.21,398.61,195.51,211.7
└ Non-current3,383.52,861.12,483.81,535.03,214.13,316.94,300.04,453.6
Trade payables1,192.71,460.71,538.41,335.71,533.81,828.22,479.12,734.8
Current liabilities3,843.13,596.64,369.35,237.33,766.34,159.74,758.35,158.5
Total liabilities7,749.17,017.87,400.47,334.67,552.18,115.69,802.410,372.5
Net debt4,770.13,808.93,931.64,234.74,199.33,971.44,140.14,835.3
Debt / equity0.810.570.580.590.580.580.670.69
Current ratio1.261.381.251.031.541.431.511.41

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow483.9508.31,004.5184.7892.3889.81,652.6390.9
└ Capex(964.8)(323.1)(712.0)(260.2)(664.4)(433.2)(890.0)(858.7)
Free cash flow(480.9)185.1292.5(75.4)227.9456.5762.6(467.8)
Investing cash flow(1,338.8)(107.2)(434.0)(74.4)(477.5)(468.3)(826.0)(970.5)
Financing cash flow817.8(386.5)(422.4)(262.5)(440.8)(361.0)(39.0)(131.3)
└ Dividends paid(67.0)0.00.0(14.5)(14.5)(18.6)(18.6)0.0
└ Buybacks0.0(13.2)(14.1)0.00.00.00.00.0
Net change in cash(37.1)14.6148.2(157.5)(26.0)60.5793.9(686.1)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

PPLPHARMA at a glance

  • PPLPHARMA closed at ₹239.3 on 20 Nov 2026, -0.15% on the day, +23.3% over one year, 5.8% below its 52-week high of ₹253.9.
  • Delivery was 45.6% of traded quantity on 20 Nov 2026, the 57th percentile of its own 1,014 sessions with a reading (20-session average 39.4%, 1-year average 38.7%).
  • Market capitalisation is ₹31,859 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-1.57).
  • Q2 FY27 results (consolidated, filed 27 Oct 2026): revenue ₹2,617 crore (+28.1% year on year), net profit ₹5 crore; the price moved +17.1% on the first session after.
  • Promoters held 34.80% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 28 Jan 2027 and 9 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0DK501011
SeriesEQ
Listed19 Oct 2022
NSE market cap · 17 Nov 2026₹32,046 Cr
Free-float market cap (NSE)₹14,912 Cr
Shares outstanding (NSE)133.13Cr
History from19 Oct 2022
Sessions1,015
Turnover rank#94

Sector history

  1. to 16 Aug 2026Index industry · Healthcare
  2. from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

NSE’s own classification, by the snapshot it changed on.

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.